Press Releases Amniotics AB

Equities

AMNI

SE0015961016

Market Closed - Nasdaq Stockholm Other stock markets 11:01:59 2024-06-07 am EDT			5-day change	1st Jan Change
0.0042 ^SEK	+10.53%		+7.69%	-53.33%

May. 20	Magle Chemoswed Holding AB (OM:MAGLE) cancelled the acquisition of 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other.	CI
Mar. 22	Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group	May. 30	AQ
Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering	May. 30	AQ
Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement	May. 21	AQ
Magle Group will not complete the public offer to the shareholders of Amniotics	May. 20	AQ
MAGLE GROUP REPORTS OUTCOME AND EXTENDS THE ACCEPTANCE PERIOD FOR THE PUBLIC TENDER OFFER TO THE SHAREHOLDERS OF AMNIOTICS	May. 07	AQ
Magle Chemoswed Q1 - Expansion by acquisition	Apr. 19	AQ
Magle Chemoswed Holding AB publishes offer document and announces updated timetable regarding the cash offer to the shareholders of Amniotics AB	Apr. 05	AQ
Magle Chemoswed Holding AB (publ) withdraws dividend proposal and enters into term loan facilities amounting to SEK 12 million in total	Mar. 22	AQ
Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed	Mar. 22	AQ
Magle Chemoswed Holding AB announces a recommended cash offer of SEK 0.004 per share to the shareholders of Amniotics AB	Mar. 22	AQ
Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement	Mar. 21	AQ
Amniotics announces the outcome of the exercise of warrants series TO 3	Mar. 11	AQ
The exercise period for warrants series TO 3 in Amniotics begins today	Feb. 26	AQ
Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding	Feb. 26	AQ
Amniotics AB (publ) Report for the fourth quarter 2023.	Feb. 22	AQ
Information about the Annual General Meeting and appointed Nomination Committee of Amniotics	Dec. 21	AQ
Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation	Dec. 14	AQ
Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study	Nov. 28	AQ
Amniotics AB (publ) Report for the third Quarter 2023	Nov. 27	AQ
Renewed GMP certification	Nov. 23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Amniotics AB

Equities

AMNI

SE0015961016

Press Releases

Filters